Mark Cunningham v. HHS - Tdap, Guillain-Barre syndrome (GBS) and/or chronic inflammatory demyelinating polyneuropathy (CIDP) (2025)
Case summary [AI summaries can sometimes make mistakes]
On February 24, 2022, Mark Cunningham filed a petition alleging that a Tdap vaccine administered on April 30, 2020 caused Guillain-Barre syndrome and/or chronic inflammatory demyelinating polyneuropathy. The public stipulation identifies him as an adult petitioner but does not provide his exact age.
Respondent denied that Mr. Cunningham suffered vaccine-caused GBS, CIDP, or any other vaccine-related injury and denied that his current condition was a sequela of vaccination.
The public stipulation does not describe his first neurologic symptom, diagnostic testing, hospitalization, treatment, or residual limitations. The parties resolved the matter by joint stipulation.
On October 23, 2025, Special Master Jennifer A. Shah adopted the stipulation and awarded Mr.
Cunningham $110,000.00 as a lump sum through counsel's IOLTA account.
Theory of causation
Adult petitioner; Tdap vaccine April 30, 2020; alleged GBS and/or CIDP. COMPENSATED by stipulation. Respondent denied diagnosis/causation/sequelae. Public stipulation lacks onset, testing, treatment, expert, and residual detail. Award $110,000.00 lump sum. SM Jennifer A. Shah October 23, 2025. Petition filed February 24, 2022. Attorney Nancy Meyers.
Source PDFs
USCOURTS-cofc-1_22-vv-00211